EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 103 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Immunotherapy for Breast Cancer Treatment: Is It an Option? September 21, 2020 This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... March 22, 2019 Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer November 24, 2021 Cancer Moonshot℠ Workshop Highlights Recent Research Advances March 4, 2020 Load more HOT NEWS Por qué no voy a “superar” los efectos a largo plazo... Coping With the Difficult Times of Cancer Survivorship Through My “Bucket... How Having a Creative Outlet Helped Me Cope During Cancer HTAN: Mapping Tumors across Space and Time Using Cutting-Edge Technologies
